Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Succession of DKFZ Chairman and Scientific Director open

Wolfgang Wick to remain at Heidelberg University Hospital

No. 33 | 14/07/2015 | by Sel

Heidelberg University Hospital and the German Cancer Research Center have announced that, following a short period of negotiations, the Medical Director of the Department of Neurology at Heidelberg University Hospital, Professor Dr. Wolfgang Wick, will no longer be assuming the position of Chairman and Scientific Member of the Management Board of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).


“We regret that Wolfgang Wick will not be taking over the position of Chairman and Scientific Director at the German Cancer Research Center,” said the Members of the DKFZ Management Board, Professor Otmar D. Wiestler (Chairman and Scientific Director) and Professor Josef Puchta (Administrative-Commercial Director).

“Professor Wick will further expand the National Center for Tumor Diseases. For this important role, it is essential that he continues his work in clinically oriented research,” says Professor Dr. Guido Adler, Chief Medical Director and Chairman of the Board of Heidelberg University Hospital. “We are pleased that our neurologist and excellent researcher, still in the early phases of his position in the Neurology Department, will stay at our hospital,” commented Professor Dr. Wolfgang Herzog, Dean of the Medical Faculty at Heidelberg University.

“Through his collaboration with the NCT and as head of a Clinical Cooperation Unit of DKFZ and Heidelberg University Hospital, he will continue to be closely linked with cancer research at the DKFZ,” said Wiestler with an optimistic look into the future. 

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS